COMMUNIQUÉS West-GlobeNewswire

Capricor Therapeutics to Present at PPMD Annual Conference
28/06/2018
Poster Presentation on Pre-clinical Research of CAP-2003 in Disease Model of Duchenne Muscular Dystrophy LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics ’ (NASDAQ:CAPR) chief medical officer, [...]
Neuronetics, Inc., Maker of NeuroStar® Advanced Therapy, Announces Pricing of Initial Public Offering
28/06/2018
MALVERN, Pa., June 28, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality of life for patients who [...]
Innovate Biopharmaceuticals Enters into an R&D Collaboration on Larazotide’s Corrective Effect on the Dysfunctional Intestinal Barrier and the Dysfunctional Microbiome in various Diseases with the University of Maryland School of Medicine
28/06/2018
RALEIGH, N.C., June 28, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals Inc . (Nasdaq:INNT), a clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases, [...]
ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
28/06/2018
The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene. QR-313 is a first-in-class potential [...]
Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs
28/06/2018
Board Comprises Six Members with Notable Contributions to the Fields of Oncology and Immunology BERKELEY, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the [...]
Hydropothecary reports fiscal 2018 third quarter results
28/06/2018
GATINEAU, Quebec, June 28, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (TSX:HEXO) (the "Company") reported its financial results for the three and nine months ended April 30, 2018, the third quarter of the [...]
Hydropothecary déclare les résultats du troisième trimestre de l’exercice 2018
28/06/2018
GATINEAU, Québec, 28 juin 2018 (GLOBE NEWSWIRE) -- La société Hydropothecary (TSX:HEXO) (la « Société ») a publié ses résultats financiers pour les périodes de trois et neuf mois closes le 30 avril 2018, à savoir le [...]
PotNetwork Holdings, Inc. Exhibits Swiftly Growing MediPets Line at Industry Leading SuperZoo Event
28/06/2018
MediPets Comes to Vegas Bringing the Latest in Pet CBD to the Largest Industry Event Geared Toward Professionals and Consumers Seeking Cutting-Edge Products and Education FT. LAUDERDALE, Fla., June 28, 2018 (GLOBE [...]
Amarin Reports Last Patient Study Visit Has Occurred, an Important Step Towards Completion of REDUCE-IT™ Cardiovascular Outcomes Study
28/06/2018
Study Remains On-Track for Q3 2018 Top-Line Results BEDMINSTER, N.J., and DUBLIN, Ireland, June 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the [...]
Saniona awarded grant of SEK 1.4 million for Kv7 program
28/06/2018
PRESS RELEASE June 28, 2018 Saniona, a leading biotech company within ion-channel research, today announced that it that it has received a research grant of DKK 1 million (SEK 1.4 million) under the Danish Innovation [...]
Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3
28/06/2018
Bagsværd, Denmark, 28 June 2018 - Novo Nordisk today announced the headline results from PIONEER 3, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide is an [...]
Shire plc : Rule 2.9 announcement
28/06/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 28 June 2018 Shire [...]
Interim report September 1, 2017 - May 31, 2018
28/06/2018
Company announcement no.11/2018 Report attached For further information, please contact: Martin Riise, Head of Investor Relations Tel: +45 53 39 22 50 Helle Rexen, Interim Head of Media Relations Tel: +45 20 74 28 40 [...]
ESPERITE (ESP) : European Select Growth Opportunities Fund subscribes to the 20th tranche of investment today
28/06/2018
Amsterdam, The Netherlands - 28 June 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a 20 th Tranche of EUR 400,000 is issued as a private placement of 40 convertible notes (the "Notes [...]
Sanofi : Sanofi and Advent finalize negotiations for the acquisition of Zentiva
28/06/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Advent finalize negotiations for the acquisition of Zentiva PARIS - June 28, 2018 - Sanofi and Advent International ("Advent") have finished [...]
Sanofi : Sanofi et Advent finalisent les négociations sur l'acquisition de Zentiva
28/06/2018
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) Sanofi et Advent finalisent les négociations sur l'acquisition de Zentiva Paris - Le 28 juin 2018 - Sanofi et Advent International (« Advent ») [...]
argenx receives second preclinical milestone payment under its development agreement with AbbVie
28/06/2018
June 28, 2018 Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Forty Seven Prices Initial Public Offering
28/06/2018
MENLO PARK, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical stage immuno-oncology company, announced today the pricing of its initial public offering of 7,035,000 shares of common [...]
Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018
27/06/2018
Patient enrollment in the two TRILOGY Phase 3 studies is progressing as planned: 463 patients enrolled and 41 patients randomized at 110 clinical sites as of June 26 th Phase 3 topline results tracking on schedule to be [...]

Pages